Introduction: Few studies have demonstrated the cost burden of cardiovascular events (CVEs) among patients with hyperlipidemia. The primary objective of this study was to determine the mean costs associated with CVEs among patients with hyperlipidemia by follow-up time period. Secondary objectives of this study included characterizing costs by CVE type and coronary heart disease (CHD) risk. Methods: This retrospective cohort study used longitudinal claims to calculate payer costs according to CHD risk level and type of CVE, during several follow-up periods (acute and short-term, comprising year 1; plus years 2 and 3). Results: There were 193,385 patients with hyperlipidemia with a CVE. Costs in the acute (30-day) period were highest ($22,404) driven by inpatient care (77%). Costs remained high ($15,133 in year 3) with ambulatory care (from 14% in acute to 37% in year 3) and pharmaceutical costs (from 2% in acute to 24% in year 3) representing a greater proportion. After second and third CVEs, acute costs were lower than for the first CVE. But in the post-acute periods, costs were higher after second and third CVEs than after first CVEs. Acute costs varied considerably by type of CVE ($9149 for transient ischemic attack to $54,251 for coronary artery bypass graft; P\0.001), but post-acute costs were more similar across types. Costs differed by baseline CHD risk for all follow-up periods (P\0.001), but less than by CVE type. As expected, patients without CVEs had significantly lower costs. Conclusion: Among patients with hyperlipidemia, the economic burden of CVEs is substantial up to 3 years after a CVE. Costs remain high after subsequent CVEs and actually increase for non-inpatient utilization. Funding: Amgen Inc. Electronic supplementary material The online version of this article (
INTRODUCTION
The treatment and prevention of hyperlipidemia (elevated low-density lipoprotein-C [LDL-C] levels) have been a significant public health focus for many years.
Elevated LDL-C is associated with increased risk of developing coronary heart disease (CHD), the most common cause of death in the United States (US) [1, 2] . Meta-analysis of 26 clinical trials demonstrated that risk of any cardiovascular event (CVE) was reduced by 20% and mortality was reduced by 10%, for every 38.7 mg/dL reduction of LDL-C [2] .
Another more recent meta-analysis demonstrated among 40 trials of lipid-modifying drugs that LDL-C, but not high-density lipoprotein, levels were predictive of both primary and secondary CVEs [3] . The newest American College of Cardiology/
American Heart Association Task Force on
Practice Guidelines defined the characteristics of patients who would most benefit from statin therapy to treat hyperlipidemia and prevent CVEs, including atherosclerotic cardiovascular disease (ASCVD), elevated LDL-C, diabetes, and high estimated 10-year ASCVD risk [4] . Yet, even though high LDL-C affects 71 million (33.5%) US adults, \50% of affected individuals receive treatment [1] .
Cardiovascular disease (CVD) and stroke are major contributors of disease burden in the US [5] , and globally [6] . In the US, the annual direct cost of CVD and stroke was estimated at $192.1 billion in 2009: Approximately $86.1 billion for inpatient stays, $46.7 billion for outpatient or office-based visits, and $31.8 billion for prescription drugs [7] . Costs related to CVEs include acute treatment, secondary prevention measures, recurrent
CVEs, and rehabilitation [7] [8] [9] [10] [11] [12] [13] [14] . Age, hyperlipidemia, impaired renal function, depression, and concurrent CVEs have been shown to impact costs [8, [15] [16] [17] [18] [19] .
Previous research has been valuable in demonstrating the great cost burden of CVEs [8, 16, [20] [21] [22] ], yet only one report specifically assessed cohorts of patients with hyperlipidemia. Given that adequate hyperlipidemia treatment lowers the risks associated with CVEs, it is important to obtain current cost estimates associated with CVEs.
The primary objective of this study was to determine the mean costs associated with CVEs among patients with hyperlipidemia by follow-up time period. Secondary objectives of this study included characterizing costs by CVE type and CHD risk; as a reference, we provide cost estimates for a sample of non-CVE patients from the same population.
METHODS

Study Design
This was a retrospective cohort study using longitudinal administrative healthcare claims data. Healthcare costs were calculated by baseline level of CHD risk and type of CVE during several follow-up periods: Acute (days 0-30), short-term (days 31-365), first year (days 0-365), second year (days 366-730),
and third year (days 731-1095). Costs of first and subsequent CVEs were also obtained. Costs were compared to patients not experiencing a CVE but with similar baseline characteristics.
Data Sources
Data were obtained from the Optum Research Database (ORD), which contains de-identified medical and pharmacy claims data annually for approximately 14 million individuals who are enrolled in a commercial (fully insured or self-insured employer line of business) or Medicare Advantage plan. This paper reports results among commercial health plan enrollees only. The population contained within ORD is geographically diverse and fairly representative across the US, with a concentration of patients in the South. The ORD does not contain protected health information and is fully compliant with federal guidance on human subjects research, thus IRB review and approval was not required [23] .
Study Sample
Subjects included members C18 years old with hyperlipidemia identified by a claim for a hyperlipidemia drug (see Table S1 in the online supplementary material) or an International Classification of Diseases Clinical Modification 9 (ICD-9-CM) [24] Multiple types of CVEs [myocardial infarction (MI), ischemic stroke (IS), transient ischemic attack (TIA), heart failure (HF), unstable angina (UA), percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG)] were studied. The CVEs were identified by the presence of ICD-9-CM or healthcare common procedure coding system (HCPCS) [25] codes: C1 ICD-9-CM facility claims for hospitalizations for MI, IS, TIA, HF, or UA, or C1 ICD-9-CM or HCPCS procedure claims for PCI or CABG (see Table S2 Table S3 in the online supplementary material 
RESULTS
Sample Description
The (Table 2) .
This pattern continued for those experiencing a second (n = 84,386) and third CVE (n = 52,977), but in contrast, costs were greater in the short-term versus acute period (Fig. 1) . These patterns were similar across CVE type.
Costs by CVE Risk Level
The costs for each of the follow-up periods, by risk level, are shown in Table 3 and Fig. 2 . Interestingly, mean costs differed by baseline CHD risk for all time periods (overall P\0.001), but without a consistent pattern in the acute period for the CVE cohort. However, short-term, second-year, and third-year patterns were more similar (Fig. 2 ) between years and among risk levels, with third-year costs lower than second-year costs. Although remaining significantly different (overall P\0.001) by types, costs beyond the first 30 days (short-term, second year, third year) varied less by index CVE type. In the second and third years, HF was the costliest type, while CABG was the least costly.
Costs by Type of CVE
Costs Among Patients with no CVE
A total of 154,354 patients with hyperlipidemia but not experiencing a CVE were selected among those with a similar PS to patients experiencing a CVE. Characteristics used in the PS model were similar except a few distinctions (e.g., age and risk level) which can be attributed to the fact that patients with CVEs are typically older and at higher risk due to the inherent nature of the disease. As expected, patients without a CVE were found to have much lower costs in each of the time periods overall and within each CHD risk level (Fig. 2) . Acute period costs for those with no CVE were very low compared to those with a CVE, but costs over the follow-up time periods in both groups were substantial and remained relatively steady across risk level. However, follow-up costs were double for those experiencing a CVE than those not experiencing a CVE.
DISCUSSION
The importance of this study was the focus upon the costs incurred by commercial payers following a CVE within a population of patients with hyperlipidemia, to further understand the economic burden associated with CVD among this high-risk population.
Prior [16] ) comparing costs between patients with and without CVEs. Similar to the current study, these authors found CVEs imparted significantly greater inpatient, outpatient, and prescription costs, and high continuing costs during up to three follow-up years [16] . Chapman et al. [8] conducted an observational study on costs of CVEs using dyslipidemia as one of the potential confounders in a multivariable analysis. In their study, mean total costs were at $33,563 for the first year, compared to $41,937 in the current study [8] . A recent study by Punekar et al. [22] investigated healthcare resource utilization and costs. Some similarities exist between studies: Those with CVEs had higher healthcare costs than matched controls, and CABG and TIA events were associated with highest and lowest costs, respectively [22] . Punekar et al. [22] 
CONCLUSIONS
The costs associated with CVEs among patients with hyperlipidemia are high and remain elevated. The CVE costs are largely driven by inpatient hospitalization in the first 30 days, CHD coronary heart disease, CVE cardiovascular event, SD standard deviation but significant costs persist for several years. After the acute period, outpatient and ambulatory costs represent a larger proportion of costs. The main driver of CVE costs in this study is CHD risk level, with costs varying by index CVE type. To assess the impact of lipid-lowering medications, a similar study including variables on medication use is necessary. Future clinical decision-making and cost-effectiveness studies will benefit from these findings.
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